Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140577 | 1.00 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL4551880 | 0.84 | MEN1 (0.65) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL27789357 | 0.76 | MEN1 (0.48) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28567227 | 0.72 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL460472 | 0.72 | NPC1 (0.65) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28591483 | 0.72 | NPC1 (0.81) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28572318 | 0.70 | RAB9A (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28561315 | 0.70 | RAB9A (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28561316 | 0.70 | RAB9A (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28561361 | 0.70 | NPC1 (0.60) | NPC1RAB9AMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| CN-101610674-A | Sphingosine-1-phosphate ester receptor stimulating agent and agonist compounds | ABBOTT LAB (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2120575-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | Abbott Laboratories (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | S1PR1, S1PR3, S1PR5 | NPC1 396/4885RAB9A 2935/4885MEN1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.